CHDM
MCID: CHR072
MIFTS: 61

Chordoma (CHDM) malady

Categories: Rare diseases, Genetic diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Chordoma

Aliases & Descriptions for Chordoma:

Name: Chordoma 54 50 24 25 56 66 13 52 42 69
Chordoma, Susceptibility to 54 29
Notochordal Sarcoma 25 56
Chdm 25 66
Chordoepithelioma 25
Chordocarcinoma 25
Notochordoma 25

Characteristics:

Orphanet epidemiological data:

56
chordoma
Inheritance: Autosomal dominant,Not applicable; Prevalence: <1/1000000 (United States); Age of onset: Adult; Age of death: any age;

HPO:

32
chordoma:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 56  
Rare endocrine diseases


External Ids:

OMIM 54 215400
Orphanet 56 ORPHA178
MESH via Orphanet 43 D002817
UMLS via Orphanet 70 C0008487
ICD10 via Orphanet 34 C76.7
MedGen 40 C0008487
MeSH 42 D002817

Summaries for Chordoma

NIH Rare Diseases : 50 a chordoma is a rare tumor that develops from cells of the notochord, a structure that is present in the developing embryo and is important for the development of the spine. the notochord usually disappears before birth, though a few cells may remain embedded in the bones of the spine or at the base of the skull. chordomas can occur anywhere along the spine. approximately half of all chordomas occur at the base of the spine; approximately one third occur at the base of the skull. chordomas grow slowly, extending gradually into the surrounding bone and soft tissue. the actual symptoms depend on the location of the chordoma. a chordoma at the base of the skull may lead to double vision and headaches. a chordoma that occurs at the base of the spine may cause problems with bladder and bowel function. chordomas typically occur in adults between the ages of 40 and 70. in many cases, the cause of the chordoma remains unknown. recent studies have shown that changes in the t gene have been associated with chordomas in a small set of families. in these families an inherited duplication of the t gene is associated with an increased risk of developing a chordoma. the current treatment is often the surgical removal of the tumor, followed by radiotherapy. last updated: 11/9/2016

MalaCards based summary : Chordoma, also known as chordoma, susceptibility to, is related to chondroid chordoma and clivus chordoma, and has symptoms including abnormality of the vertebral column and abnormality of the head. An important gene associated with Chordoma is CHDM (Chordoma), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Sunitinib and nivolumab have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and pituitary, and related phenotypes are Decreased cell migration and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Genetics Home Reference : 25 A chordoma is a rare type of cancerous tumor that can occur anywhere along the spine, from the base of the skull to the tailbone. Chordomas grow slowly, gradually extending into the bone and soft tissue around them. They often recur after treatment, and in about 40 percent of cases the cancer spreads (metastasizes) to other areas of the body, such as the lungs.

OMIM : 54 Chordomas are rare, clinically malignant tumors derived from notochordal remnants. They occur along the length of the... (215400) more...

UniProtKB/Swiss-Prot : 66 Chordoma: Rare, clinically malignant tumors derived from notochordal remnants. They occur along the length of the spinal axis, predominantly in the sphenooccipital, vertebral and sacrococcygeal regions. They are characterized by slow growth, local destruction of bone, extension into adjacent soft tissues and rarely, distant metastatic spread.

Wikipedia : 71 Chordoma is a rare slow-growing neoplasm thought to arise from cellular remnants of the notochord. The... more...

Related Diseases for Chordoma

Diseases related to Chordoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 239)
id Related Disease Score Top Affiliating Genes
1 chondroid chordoma 12.2
2 clivus chordoma 12.2
3 spinal chordoma 12.2
4 clivus chondroid chordoma 12.1
5 sacrum chordoma 12.1
6 cervicitis 10.4
7 lucey-driscoll syndrome 10.3 MUC1 S100B
8 secondary pulmonary hemosiderosis 10.3 MUC1 S100B
9 inflammatory linear verrucous epidermal nevus 10.3 DES VIM
10 glucosidase acid-1,4-alpha deficiency 10.3 DES GFAP
11 ovarian insufficiency due to fsh resistance 10.3 MET MUC1 VIM
12 chondrosarcoma 10.3
13 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 10.3 MUC1 S100B VIM
14 subglottis verrucous carcinoma 10.3 MUC1 S100B VIM
15 conjunctival cancer 10.3 MUC1 S100B VIM
16 clear cell ependymoma 10.3 MUC1 S100B VIM
17 differentiating neuroblastoma 10.2 CDH1 MUC1 VIM
18 endometrial stromal sarcoma 10.2 GFAP MUC1 VIM
19 benign schwannoma 10.2 S100B VIM
20 lymphomatous thyroiditis 10.2 DES VIM
21 precursor t-lymphoblastic lymphoma/leukemia 10.2 EGFR MUC1 S100B
22 marfanoid hypermobility syndrome 10.2 DES MUC1 VIM
23 childhood brain germinoma 10.2 MUC1 S100B VIM
24 cauda equina intradural extramedullary astrocytoma 10.2 GFAP MUC1 VIM
25 desmoid tumor 10.2 MUC1 S100B VIM
26 sclerosing hemangioma 10.2 CDH1 EGFR MUC1
27 petrous apex meningioma 10.2 DES MUC1 VIM
28 adult brainstem gliosarcoma 10.2 GFAP MET VIM
29 myelinoclastic diffuse sclerosis 10.2 GFAP MUC1 S100B
30 coronary stenosis 10.2 DES MUC1 VIM
31 sebaceous adenoma 10.2 DES MUC1 VIM
32 anal gland neoplasm 10.2 DES MUC1 VIM
33 urethral cancer 10.2 DES MET VIM
34 trombiculiasis 10.2 GFAP MUC1 S100B
35 omodysplasia 2 10.2 DES MUC1 VIM
36 cervical lymphoepithelioma-like carcinoma 10.2 EGFR MUC1
37 bladder adenocarcinoma 10.2 CDKN2A MUC1 VIM
38 congenital muscular dystrophy with hyperlaxity 10.2 DES MUC1 VIM
39 porokeratosis 10.2 GFAP MUC1 S100B
40 breast squamous cell carcinoma 10.2 GFAP MUC1 VIM
41 avian influenza 10.2 CDKN2A MUC1 VIM
42 lung benign neoplasm 10.2 DES MUC1 VIM
43 orthostatic proteinuria 10.2 DES MUC1 VIM
44 his bundle tachycardia 10.2 EGFR S100B VIM
45 dental caries 10.2 CDH1 EGFR MUC1
46 nasal cavity disease 10.2 CDH1 EGFR MUC1
47 vagina leiomyosarcoma 10.2 DES GFAP MUC1
48 bronchitis 10.2 CDH1 GFAP
49 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 10.2 GFAP S100B VIM
50 thymic dysplasia 10.2 MUC1 NCAM1

Graphical network of the top 20 diseases related to Chordoma:



Diseases related to Chordoma

Symptoms & Phenotypes for Chordoma

Symptoms by clinical synopsis from OMIM:

215400

Clinical features from OMIM:

215400

Human phenotypes related to Chordoma:

32
id Description HPO Frequency HPO Source Accession
1 abnormality of the vertebral column 32 HP:0000925
2 abnormality of the head 32 HP:0000234
3 chordoma 32 HP:0010762

GenomeRNAi Phenotypes related to Chordoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.43 EGFR JUP MET MUC1 NCAM1 VIM
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.02 EGFR JUP MUC1 PTEN VIM

MGI Mouse Phenotypes related to Chordoma:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.33 CDH1 CDKN2A DES EGFR GFAP JUP
2 cellular MP:0005384 10.31 PTEN VIM CDH1 CDKN2A DES EGFR
3 homeostasis/metabolism MP:0005376 10.31 CDH1 CDKN2A DES EGFR GFAP JUP
4 behavior/neurological MP:0005386 10.3 GFAP LGALS3 MET NCAM1 PDGFRA PTEN
5 mortality/aging MP:0010768 10.25 CDKN2A DES EGFR GFAP JUP LGALS3
6 digestive/alimentary MP:0005381 10.18 CDH1 CDKN2A EGFR GFAP LGALS3 MET
7 immune system MP:0005387 10.18 CDH1 CDKN2A EGFR GFAP JUP LGALS3
8 embryo MP:0005380 10.16 CDH1 CDKN2A EGFR JUP MET PDGFRA
9 integument MP:0010771 10.11 CDH1 CDKN2A EGFR JUP LGALS3 PDGFRA
10 muscle MP:0005369 10.06 CDKN2A DES EGFR GFAP JUP MET
11 nervous system MP:0003631 10.06 CDKN2A EGFR GFAP JUP LGALS3 MET
12 neoplasm MP:0002006 9.91 CDH1 CDKN2A EGFR LGALS3 MET PDGFRA
13 normal MP:0002873 9.91 CDH1 EGFR GFAP JUP MET PDGFRA
14 reproductive system MP:0005389 9.76 CDH1 CDKN2A EGFR LGALS3 PDGFRA PTEN
15 respiratory system MP:0005388 9.56 CDKN2A EGFR JUP LGALS3 MET PDGFRA
16 vision/eye MP:0005391 9.17 MET NCAM1 PTEN VIM CDKN2A EGFR

Drugs & Therapeutics for Chordoma

Drugs for Chordoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
2
nivolumab Approved Phase 2,Phase 1 946414-94-4
3
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
4
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
5
Palbociclib Approved Phase 2 571190-30-2 11431660 5005498 5330286
6 Imatinib Mesylate Phase 2,Phase 1 123596
7 Protein Kinase Inhibitors Phase 2,Phase 1
8 Angiogenesis Inhibitors Phase 2
9 Angiogenesis Modulating Agents Phase 2
10 Immunosuppressive Agents Phase 2,Phase 1
11 Vaccines Phase 2
12 Antibodies Phase 2,Phase 1
13 Antibodies, Monoclonal Phase 2,Phase 1
14 Immunoglobulins Phase 2,Phase 1
15 Dermatologic Agents Phase 2,Phase 1
16 Dihematoporphyrin Ether Phase 2,Phase 1
17 Ether Phase 2,Phase 1
18 Hematoporphyrin Derivative Phase 2,Phase 1
19 Hematoporphyrins Phase 2,Phase 1
20 Pharmaceutical Solutions Phase 2
21 Photosensitizing Agents Phase 2,Phase 1
22
Cobalt Phase 2 7440-48-4 104729
23 Brewer's Yeast Nutraceutical Phase 2
24 lysine Nutraceutical Phase 2,Phase 1
25
Panobinostat Approved, Investigational Phase 1 404950-80-7 6918837
26
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
27
Amifostine Approved, Investigational Phase 1 20537-88-6 2141
28
Busulfan Approved, Investigational Phase 1 55-98-1 2478
29
Lenograstim Approved Phase 1 135968-09-1
30
Melphalan Approved Phase 1 148-82-3 4053 460612
31
Thiotepa Approved Phase 1 52-24-4 5453
32 Histone Deacetylase Inhibitors Phase 1
33 Mitogens Phase 1
34 Adjuvants, Immunologic Phase 1
35 Protective Agents Phase 1
36 Alkylating Agents Phase 1
37 Antineoplastic Agents, Alkylating Phase 1
38 Antirheumatic Agents Phase 1
39 Liver Extracts Phase 1
40 Radiation-Protective Agents Phase 1
41
Hyaluronic acid Approved, Vet_approved 9004-61-9 53477741 24759
42
Menthol Approved 2216-51-5 16666
43 Blood Substitutes
44 Plasma Substitutes
45 Povidone
46 Viscosupplements
47 Anti-Infective Agents
48 Antiparasitic Agents
49 Antiprotozoal Agents
50 Misonidazole

Interventional clinical trials:

(show all 42)
id Name Status NCT ID Phase
1 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
2 Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base Recruiting NCT01182779 Phase 3
3 Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors Not yet recruiting NCT02838602 Phase 3
4 Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine Unknown status NCT00592748 Phase 1, Phase 2
5 Efficacy and Safety of Imatinib in Chordoma Completed NCT00150072 Phase 2
6 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
7 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2
8 Ion Irradiation of Sacrococcygeal Chordoma Recruiting NCT01811394 Phase 2
9 Improvement of Local Control in Skull Base, Spine and Sacral Chordomas Treated by Surgery and Protontherapy Targeting Hypoxic Cells Revealed by [18F]FAZA) PET/CT Tracers Recruiting NCT02802969 Phase 2
10 The National Cancer Institute Opens A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma Recruiting NCT02383498 Phase 2
11 Proton Radiation for Chordomas and Chondrosarcomas Recruiting NCT01449149 Phase 1, Phase 2
12 A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas Recruiting NCT02389244 Phase 2
13 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2
14 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
15 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Recruiting NCT01966809 Phase 2
16 Proton Beam Therapy for Chordoma Patients Active, not recruiting NCT00496119 Phase 2
17 Trial of Dasatinib in Advanced Sarcomas Active, not recruiting NCT00464620 Phase 2
18 CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma Not yet recruiting NCT03110744 Phase 2
19 Afatinib in Locally Advanced and Metastatic Chordoma Not yet recruiting NCT03083678 Phase 2
20 Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Not yet recruiting NCT03173950 Phase 2
21 Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma Unknown status NCT01175109 Phase 1
22 Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate Completed NCT01046487 Phase 1
23 Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma Recruiting NCT02989636 Phase 1
24 A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma Recruiting NCT02601937 Phase 1
25 HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors Recruiting NCT00931931 Phase 1
26 Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies Recruiting NCT01924689 Phase 1
27 Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors Recruiting NCT01682746 Phase 1
28 Nilotinib With Radiation for High Risk Chordoma Active, not recruiting NCT01407198 Phase 1
29 Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Terminated NCT00003926 Phase 1
30 Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer Unknown status NCT00349024
31 Chordoma Family Study Completed NCT00410670
32 Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families Completed NCT00341627
33 Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas Completed NCT00713037
34 Proton Therapy for Chordomas and/or Chondrosarcomas Completed NCT00797602
35 Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas Completed NCT01567046
36 Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes Recruiting NCT01200680
37 Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease Recruiting NCT02986516
38 A Study of IMRT in Primary Bone and Soft Tissue Sarcoma Recruiting NCT02520128
39 Effect of High Doses of Radiation on Bone Structure and Metabolism Recruiting NCT02323295
40 Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Recruiting NCT00919269
41 High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull Active, not recruiting NCT01346124
42 Stereotactic Body Radiotherapy for Spine Tumors Active, not recruiting NCT01347307

Search NIH Clinical Center for Chordoma

Cochrane evidence based reviews: chordoma

Genetic Tests for Chordoma

Genetic tests related to Chordoma:

id Genetic test Affiliating Genes
1 Chordoma 29 24

Anatomical Context for Chordoma

MalaCards organs/tissues related to Chordoma:

39
Bone, Lung, Pituitary, Thyroid, Endothelial, Breast, Lymph Node

Publications for Chordoma

Articles related to Chordoma:

(show top 50) (show all 783)
id Title Authors Year
1
Whole-Body MRI Virtual Autopsy Using Diffusion-weighted Imaging With Background Suppression (DWIBS) at 3 T in a Child Succumbing to Chordoma. ( 28060123 )
2017
2
Spinal stereotactic body radiotherapy following intralesional curettage with separation surgery for initial or salvage chordoma treatment. ( 28041314 )
2017
3
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. ( 27696380 )
2017
4
Osseous metastases of chordoma: imaging and clinical findings. ( 28064345 )
2017
5
Prognostic Factors and Survival Outcomes in Patients with Chordoma in the United States: A Population-Based Analysis. ( 28457925 )
2017
6
EM proves invaluable in the confirmation of chordoma in the sacral mass of a middle-aged man. ( 28524812 )
2017
7
Genetic aberrations and molecular biology of skull base chordoma and chondrosarcoma. ( 28432450 )
2017
8
UM-Chor1: establishment and characterization of the first validated clival chordoma cell line. ( 28430034 )
2017
9
A Case of Coincidental Intrasellar Chordoma and Pituitary Adenoma. ( 28516081 )
2017
10
Erratum to: Symptom burden and life challenges reported by adult chordoma patients and their caregivers. ( 28527124 )
2017
11
Erratum. UM-Chor1: establishment and characterization of the first validated clival chordoma cell line. ( 28524794 )
2017
12
Prognostic Factors in Patients With Spinal Chordoma: An Integrative Analysis of 682 Patients. ( 28368502 )
2017
13
Clival chordoma: a single-centre outcome analysis. ( 28478512 )
2017
14
Variables affecting functional improvement in chordoma patients admitted to an inpatient rehabilitation facility: A retrospective review. ( 28464722 )
2017
15
On a Rare Cutaneous Metastasis from a Sacrococcygeal Chordoma. ( 28409046 )
2017
16
MR Imaging Grading System for Skull Base Chordoma. ( 28428207 )
2017
17
Recurrent chordoma with orbital and eyelid invasion. ( 28357494 )
2017
18
Pediatric Clival Chordoma: A Curable Disease that Conforms to Collins' Law. ( 28521059 )
2017
19
Updated Outcome and Analysis of Tumor Response in Mobile Spine and Sacral Chordoma Treated With Definitive High-Dose Photon/Proton Radiation Therapy. ( 27986348 )
2017
20
Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients. ( 28059654 )
2017
21
Answer to the Letter to the Editor of J. Li et al. concerning "Surgical treatment of sacral chordoma: survival and prognostic factors" by C. Ruosi et al. (Eur Spine J; 2015; 24(Suppl 7):S912-S917). ( 27766429 )
2017
22
Chordoma Occurs in Young Children With Tuberous Sclerosis. ( 28498973 )
2017
23
Prognostic Significance of Resection Degree in Skull Base Chordoma: A Systematic Review and Meta-Analysis. ( 28437876 )
2017
24
Letter to the Editor concerning "Surgical treatment of sacral chordoma: survival and prognostic factors" by C. Ruosi et al. (Eur Spine J; 2015; 24(Suppl 7):S912-S917. ( 27757683 )
2017
25
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. AA retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression FranAsaise (ANOCEF). ( 28478340 )
2017
26
In Reply: Factors Predicting Recurrence After Resection of Clival Chordoma Using Variable Surgical Approaches and Radiation Modalities. ( 28379552 )
2017
27
Laser interstitial thermal therapy for palliative ablation of a chordoma metastasis to the spine: case report. ( 28362211 )
2017
28
In Reply to "Prognostic Significance of Resection Degree inA Skull Base Chordoma: A Systematic Review and Meta-Analysis". ( 28437877 )
2017
29
Erratum to: PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. ( 27161248 )
2016
30
Upregulated human telomerase reverse transcriptase (hTERT) expression is associated with spinal chordoma growth, invasion and poor prognosis. ( 27158344 )
2016
31
Tumor size as a Prognostic Factor in Spinal Chordoma: A Systematic Literature Review. ( 27753788 )
2016
32
Fine needle aspiration cytology aided diagnosis of chordoma at an unusual site. ( 27018015 )
2016
33
Whole-transcriptome analysis of chordoma of the skull base. ( 27401718 )
2016
34
Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR. ( 27200287 )
2016
35
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). ( 27659533 )
2016
36
High-intensity focused ultrasonic ablation of sacral chordoma is feasible: a series of four cases and details of a national clinical trial. ( 27936948 )
2016
37
Giant chordoma in the thoracolumbar spine: a case report and literature review. ( 27900552 )
2016
38
CORR Insights(Ar): What are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients with Sacral Chordoma? ( 27184140 )
2016
39
Spine extra-osseous chordoma mimicking neurogenic tumors: report of three cases and review of the literatures. ( 27491867 )
2016
40
PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma. ( 27002766 )
2016
41
Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series. ( 27822356 )
2016
42
Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute. ( 27942938 )
2016
43
Immunotherapy as a Potential Treatment for Chordoma: a Review. ( 27475804 )
2016
44
Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. ( 27172898 )
2016
45
Upregulation of metastasis-associated PRL-3 initiates chordoma in zebrafish. ( 26846972 )
2016
46
Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma. ( 27558389 )
2016
47
Genomic aberrations frequently alter chromatin regulatory genes in chordoma. ( 27072194 )
2016
48
An unusual case of acquired pedophilic behavior following compression of orbitofrontal cortex and hypothalamus by a Clivus Chordoma. ( 27159984 )
2016
49
Factors for tumor progression in patients with skull base chordoma. ( 27546605 )
2016
50
Prognostic Biomarkers in Spinal Chordoma: A Systematic Review. ( 27941139 )
2016

Variations for Chordoma

Copy number variations for Chordoma from CNVD:

7 (show top 50) (show all 470)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13362 10 1 135374737 Loss PTEN Chordoma
2 13372 17 1 22200000 Loss NF1 Chordoma
3 13373 17 1 22200000 Loss P53 Chordoma
4 13795 11 1 51400000 Loss WT1 Chordoma
5 13810 19 1 63811651 Gain BAX Chordoma
6 13811 19 1 63811651 Gain TGFB1 Chordoma
7 13825 18 1 76117153 Loss SMAD4 Chordoma
8 17403 1 142600000 180300000 Gain Chordoma
9 21008 1 15600000 106368585 Loss Chordoma
10 21654 13 16000000 114142980 Loss BRCA2 Chordoma
11 21655 13 16000000 114142980 Loss RB Chordoma
12 25739 1 193800000 243700000 Gain Chordoma
13 28392 17 22200000 78774742 Gain HER2 Chordoma
14 29289 1 2300000 124300000 Loss RUNX3 Chordoma
15 31074 1 25226001 25291501 Loss RUNX3 Chordoma
16 31348 1 26979575 26979875 Gain Chordoma
17 31733 1 30245671 30246671 Gain Chordoma
18 31901 1 31899334 31900334 Loss Chordoma
19 31908 1 31940315 31941315 Gain Chordoma
20 32031 1 32719745 32720045 Gain Chordoma
21 32032 1 32720036 32721036 Loss Chordoma
22 32207 1 34451346 34452346 Gain Chordoma
23 32675 1 38399550 38400550 Gain Chordoma
24 32770 1 39264122 39265122 Gain Chordoma
25 33966 1 50992002 50993002 Gain Chordoma
26 35065 11 59700000 74900000 Gain MEN1 Chordoma
27 36036 1 70901720 70902020 Loss Chordoma
28 36038 1 70998381 70998681 Loss Chordoma
29 36075 1 71137728 71138728 Gain Chordoma
30 48312 11 1 12700000 Loss Chordoma
31 49581 11 108093558 108239826 Loss ATM Chordoma
32 52925 11 21700000 48800000 Loss Chordoma
33 56520 11 59900000 68400000 Loss Chordoma
34 63736 12 120700000 125900000 Loss Chordoma
35 65974 12 23685230 24715380 Gain SOX5 Chordoma
36 66550 12 30700000 35800000 Loss Chordoma
37 67677 12 4382901 4414522 Gain CCND2 Chordoma
38 67847 12 4543308 4554780 Gain Chordoma
39 68279 12 48366747 48398285 Gain COL2A1 Chordoma
40 74311 13 103858404 103859404 Loss Chordoma
41 81414 14 102320080 102321080 Gain Chordoma
42 81835 14 104931320 104931620 Gain Chordoma
43 81836 14 104931398 104932398 Loss Chordoma
44 86968 14 67892033 67893033 Loss Chordoma
45 86969 14 67894685 67895685 Gain Chordoma
46 86990 14 68271232 68272232 Gain Chordoma
47 87006 14 68408332 68409332 Gain Chordoma
48 87676 14 75864127 75864427 Loss Chordoma
49 87678 14 75887005 75888005 Gain Chordoma
50 87692 14 76184263 76185263 Loss Chordoma

Expression for Chordoma

Search GEO for disease gene expression data for Chordoma.

Pathways for Chordoma

Pathways related to Chordoma according to GeneCards Suite gene sharing:

(show all 30)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 CDH1 EGFR JUP LGALS3 MET MUC1
2
Show member pathways
13.7 CDH1 CDKN2A DES EGFR GFAP MET
3
Show member pathways
12.9 CDH1 CDKN2A EGFR MET PDGFRA PTEN
4 12.48 EGFR MET PDGFRA PTEN
5
Show member pathways
12.4 EGFR MET PDGFRA PTEN
6 12.34 CDH1 DES JUP MUC1 VIM
7
Show member pathways
12.25 CDH1 EGFR JUP PTEN
8 12.11 CDKN2A EGFR MET PDGFRA PTEN VIM
9 12.1 CDH1 CDKN2A EGFR JUP MET PDGFRA
10
Show member pathways
12.06 EGFR MET PDGFRA PTEN
11 11.91 MET NCAM1 T VIM
12
Show member pathways
11.85 DES GFAP VIM
13
Show member pathways
11.84 EGFR GFAP S100B
14 11.78 EGFR GFAP LGALS3 VIM
15
Show member pathways
11.76 CDH1 EGFR MET
16 11.71 CDKN2A EGFR PDGFRA PTEN
17 11.66 CDH1 JUP MUC1 NCAM1
18 11.65 CDH1 CDKN2A EGFR
19 11.64 CDH1 EGFR MET
20 11.49 NCAM1 PDGFRA T
21 11.46 CDKN2A EGFR PDGFRA
22 11.41 CDH1 MET NCAM1
23 11.37 EGFR MET PDGFRA PTEN
24 11.3 CDH1 JUP MET
25 11.29 CDH1 EGFR MET
26 11.26 LGALS3 MUC1 NCAM1
27 11.1 CDH1 EGFR MET
28 10.92 GFAP NCAM1 PDGFRA S100B VIM
29 10.9 CDH1 VIM
30 10.74 LGALS3 S100B

GO Terms for Chordoma

Cellular components related to Chordoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CDH1 EGFR JUP LGALS3 MET MUC1
2 intermediate filament GO:0005882 9.46 DES GFAP JUP VIM
3 fascia adherens GO:0005916 9.37 DES JUP
4 catenin complex GO:0016342 9.32 CDH1 JUP
5 cytoplasmic side of plasma membrane GO:0009898 8.8 CDH1 JUP PTEN
6 plasma membrane GO:0005886 10.14 CDH1 DES EGFR JUP LGALS3 MET
7 cytoplasm GO:0005737 10.07 CDH1 CDKN2A DES EGFR GFAP JUP

Biological processes related to Chordoma according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.67 EGFR MET PDGFRA
2 MAPK cascade GO:0000165 9.67 EGFR MET NCAM1 PDGFRA
3 positive regulation of cell proliferation GO:0008284 9.65 EGFR PDGFRA PTEN S100B T
4 single organismal cell-cell adhesion GO:0016337 9.63 CDH1 EGFR JUP
5 phosphatidylinositol phosphorylation GO:0046854 9.61 EGFR MET PDGFRA
6 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.5 EGFR MET PDGFRA
7 intermediate filament organization GO:0045109 9.48 DES VIM
8 entry of bacterium into host cell GO:0035635 9.4 CDH1 MET
9 cellular response to indole-3-methanol GO:0071681 9.16 CDH1 JUP
10 learning or memory GO:0007611 9.13 EGFR PTEN S100B
11 phosphatidylinositol-mediated signaling GO:0048015 8.92 EGFR MET PDGFRA PTEN

Molecular functions related to Chordoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 DES EGFR GFAP PTEN S100B VIM
2 structural constituent of cytoskeleton GO:0005200 9.61 DES GFAP VIM
3 protein phosphatase binding GO:0019903 9.54 EGFR JUP MET
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGFR MET PDGFRA
5 glycoprotein binding GO:0001948 9.43 CDH1 EGFR VIM
6 platelet-derived growth factor receptor binding GO:0005161 9.4 PDGFRA PTEN
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR MET PDGFRA
8 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.92 EGFR MET NCAM1 PDGFRA

Sources for Chordoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....